Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2018

01-08-2018 | Gastrointestinal Oncology

Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy

Author: Takushi Yasuda, MD

Published in: Annals of Surgical Oncology | Issue 8/2018

Login to get access

Excerpt

The main goals of neoadjuvant therapy are to increase the curative resection rate by downstaging the primary tumor and to improve postoperative survival by eliminating systemic micrometastases. Chemoradiotherapy (CRT), the mainstay of preoperative therapy for advanced esophageal cancer in Western countries, has dramatically improved local control by increasing the R0 resection rate. However, distant metastasis is common, and two recent randomized clinical studies comparing neoadjuvant CRT and neoadjuvant chemotherapy (NAC) failed to demonstrate a survival benefit of neoadjuvant CRT despite its favorable local control and R0 resection rates.1,2 …
Literature
1.
Brumeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47:354–60.CrossRef
2.
Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27:660–7.CrossRefPubMed
3.
Bekkar S, Gronnier C, Renaud F, et al. Multicenter study of neoadjuvant chemotherapy for stage I and II oesophageal cancer. Br J Surg. 2016;103:855–62.CrossRefPubMed
4.
Yamasaki M, Yasuda T, Yano M, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116–20.CrossRefPubMed
5.
6.
Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol. 2016;34:2721–7.CrossRefPubMedPubMedCentral
7.
Yasuda T, Yano M, Miyata H, et al. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-positive lymph nodes following neoadjuvant chemotherapy and surgery for resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22:2599–607.CrossRefPubMed
8.
Oppedijk V, van der Gaast A, van Lanschot JJB, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.CrossRefPubMed
Metadata
Title
Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy
Author
Takushi Yasuda, MD
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6544-0

Other articles of this Issue 8/2018

Annals of Surgical Oncology 8/2018 Go to the issue

Bone and Soft Tissue Sarcomas

Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should

Gastrointestinal Oncology

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Gastrointestinal Oncology

Current Management and Future Opportunities for Peritoneal Metastases

Breast Oncology

Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database

Health Services Research and Global Oncology

Global Forum of Cancer Surgeons: A Steady Voice for Cancer Surgeons to Improve Surgical Care for Cancer Patients Globally

Breast Oncology

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes